Mayo

Questions discussed in this category

What is your current practice for de-escalation of frequency of administration of bispecific antibodies among responders in patients with relapsed/refractory multiple myeloma?

1 Answer available

What is your approach to determining fitness for patients to undergo CAR-T therapy for relapsed/refractory multiple myeloma, and any absolute perceived contraindications for CAR-T?

1 Answer available

Based on the DREAMM-7 and DREAMM-8 data, if approved again in the US, how would you incorporate belantamab mafadotin in your practice?

2 Answers available

Based on the IMROZ and BENEFIT data, would you recommend quadruplet therapy for non transplant eligible newly diagnosed multiple myeloma?

1 Answer available

What is your approach to mitigating the infection risk with bispecific antibodies in multiple myeloma?

4 Answers available

How do you choose between the different recently approved Bispecifics Antibodies for Relapsed/Refractory Multiple Myeloma?

I.e. dosing regimen frequency, side effect profile, duration of follow up, etc.

3 Answers available

How do you manage IgM related peripheral neuropathy?

Do you utilize rituximab or any other specific management strategies?

2 Answers available

Do you recommend routinely getting periodic 24-hour urine monoclonal protein study for patients with active multiple myeloma?

If so, why?

4 Answers available

Papers discussed in this category

Leukemia, 2022 Feb 21

Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio ≥100.

Br J Haematol, 2023 Jun 07

Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma.

Lancet (London, England), 2019 Dec 10

Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial.

The New England journal of medicine, 2024 Jun 03

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Nature medicine, 2024 Jun 03

Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial.

Blood, 2023 Jan 19

Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents.

The New England journal of medicine, 2024 Jun 01

Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma.

The New England journal of medicine, 2024 Jun 02

Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma.

Transplant Cell Ther, 2023 Mar 17

Safety and Efficacy of BCMA CAR-T Cell Therapy in Older Patients With Multiple Myeloma.

N Engl J Med, 2023 Jun 05

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023 Oct 24

Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy.

Blood advances, 2023 Aug 22

Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma.

Blood, 2024 Aug 08

Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study.

Nature medicine, 2023 Aug 15

Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results.

Related Topics